Reply

Affiliations

¹ Ophthalmology Consult Services Section, National Eye Institute (NEI), National Institutes of Health, Bethesda, Maryland. Electronic address: teresa.magonedequadroscosta@nih.gov.
² Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health, Bethesda, Maryland.
³ Ophthalmology Consult Services Section, National Eye Institute (NEI), National Institutes of Health, Bethesda, Maryland.
⁴ QED Therapeutics, San Francisco, California.
⁵ Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
⁶ National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health, Bethesda, Maryland.

Comment

M Teresa Magone et al. Ophthalmology. 2021 Sep.

. 2021 Sep;128(9):e44-e45.

doi: 10.1016/j.ophtha.2021.05.015. Epub 2021 Jun 21.

¹ Ophthalmology Consult Services Section, National Eye Institute (NEI), National Institutes of Health, Bethesda, Maryland. Electronic address: teresa.magonedequadroscosta@nih.gov.
² Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health, Bethesda, Maryland.
³ Ophthalmology Consult Services Section, National Eye Institute (NEI), National Institutes of Health, Bethesda, Maryland.
⁴ QED Therapeutics, San Francisco, California.
⁵ Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
⁶ National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health, Bethesda, Maryland.

No abstract available

Comment on

Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor.
Magone MT, Hartley IR, Fitzgibbon E, Bishop R, Arango M, Moran S, Vold R, Rivero JD, Pozo K, Streit J, Roszko KL, Collins MT, Gafni RI. Magone MT, et al. Ophthalmology. 2021 Apr;128(4):624-626. doi: 10.1016/j.ophtha.2020.08.026. Epub 2020 Sep 1. Ophthalmology. 2021. PMID: 32888946 Free PMC article. Clinical Trial. No abstract available.
Re: Magone et al.: Ocular adverse effects of infigratinib, a new fibroblast growth factor receptor tyrosine kinase inhibitor (Ophthalmology. 2021;128:624-626).
Francis JH, Canestraro J, Abramson DH. Francis JH, et al. Ophthalmology. 2021 Sep;128(9):e43-e44. doi: 10.1016/j.ophtha.2021.05.012. Epub 2021 Jun 21. Ophthalmology. 2021. PMID: 34167830 No abstract available.